Skip to content

BI 1467335

DRUG9 trials

Sponsors

Boehringer Ingelheim

Conditions

Diabetic RetinopathyHealthyNon-alcoholic Fatty Liver DiseaseRenal Insufficiency

Phase 1

To Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 1467335 Following Multiple Dose Administration Over 28 Days
CompletedNCT02733627
Boehringer IngelheimHealthy
Start: 2016-07-07End: 2017-07-12Updated: 2021-06-07
This Study Tests BI 1467335 in Healthy Japanese and Caucasian Men. The Study Tests How Different Doses of BI 1467335 Are Taken up in the Body and How Well They Are Tolerated
CompletedNCT03159455
Boehringer IngelheimHealthy
Start: 2017-06-07End: 2017-12-16Updated: 2021-06-04
A Study in People With Normal Kidney Function and People With Reduced Kidney Function to Test How BI 1467335 is Processed in the Body
CompletedNCT03302091
Boehringer IngelheimHealthy, Renal Insufficiency
Start: 2017-10-17End: 2018-08-16Updated: 2021-06-04
This Study Tests BI 1467335 in Healthy Male Volunteers. The Study Tests How Different Doses of BI 1467335 Are Taken up and Handled by the Body
CompletedNCT03382509
Boehringer IngelheimHealthy
Start: 2018-01-12End: 2018-04-19Updated: 2021-06-22
This Study in Healthy Men Tests How the Body Takes up BI 1467335
CompletedNCT03483506
Boehringer IngelheimHealthy
Start: 2018-04-10End: 2018-06-27Updated: 2021-07-08
A Study in Healthy Men to Test the Effects of Different Doses of BI 1467335 on MAO-B Activity in the Brain.
CompletedNCT03927209
Boehringer IngelheimHealthy
Start: 2019-06-06End: 2019-11-22Updated: 2021-06-22
A Study in Healthy People to Test How Combining BI 1467335 and Tyramine Affects Blood Pressure
TerminatedNCT03979820
Boehringer IngelheimHealthy
Start: 2019-07-31End: 2020-04-08Updated: 2021-06-04

Phase 2

Related Papers